Research Information Only — Educational content, not medical advice. Peptides discussed are research/investigational unless a specific FDA-approved brand is named. Physician review required before use.
Why This Hub Exists
Everyone's selling the shot. Nobody explains the choice.
Type any GLP-1 name into a search engine and you get two things: pharmacies selling the vial and clinics selling the appointment. What almost nobody publishes is the reasoning a clinician uses before a compound is ever chosen — how the goal, the labs, the history, and the budget decide between three drugs that look interchangeable but aren't. That reasoning is what this hub puts on the table.
The core ideaThe number on the scale is not the goal. Fat loss with lean mass preserved is the goal — and the two diverge fast when a powerful appetite suppressant is used without a plan for protein, training, and muscle protection. Every honest weight-loss protocol is built around that distinction.
The Landscape
The compounds, and the role each one plays
In a real protocol, compounds are not a menu — they're a structure. One anchor does the heavy lifting; the others are added only when a specific trigger justifies them. Here's the weight-loss roster, sorted by role.
Muscle-preservation note: for larger goals and 90-day arcs, CJC-1295 + ipamorelin (GH-axis) is frequently layered in to protect lean mass during rapid loss — see the Hormone Signaling hub.
The Differentiator
How the GLP-1 is actually chosen
This is the part no vendor shows you. Three GLP-1 compounds, and the "right" one isn't a preference — it's a decision driven by the goal and the diagnosis. Here is the selection logic, stated plainly:
GLP-1 Selection Logic
Driven by goal delta and diagnosis — the same inputs, every time, the same answer.
If type-2 diabetes is confirmed
→
Semaglutide leads — the established, diabetes-indicated GLP-1.
If goal weight loss is large (≥ 25 lb)
→
Tirzepatide — dual pathway, larger average reduction for a bigger job.
If goal weight loss is moderate (< 25 lb)
→
Retatrutide considered — where its ceiling fits without over-powering a smaller goal.
Non-negotiable rules: never two GLP-1s in one protocol · GLP-1 always its own dedicated dose, once weekly only (never a 5-on/2-off pattern) · MOTS-c pairs with the GLP-1 by default unless budget prevents it.
Why this matters for you, the readerThe reason people plateau, regain, or get wrecked by side effects is almost never the drug — it's the wrong drug for their goal, at the wrong cadence, without the metabolic and muscle-preservation supports around it. Structure beats potency.
Mechanism, Plainly
What these compounds actually do to appetite
01
They quiet "food noise"
GLP-1 receptors in the brain's appetite centers reduce the constant intrusive thinking about food. Most users describe this quieting — not raw hunger suppression — as the effect that finally changes their behavior.
02
They slow gastric emptying
Food stays in the stomach longer, so fullness arrives sooner and lasts. This is also the source of the classic GI side effects — nausea, early satiety — that titration is designed to manage.
03
They improve glucose handling
GLP-1 (and GIP, and glucagon in the triple agonist) improve insulin response and glucose regulation — which is why this class began as diabetes medicine before weight became the headline.
04
The added pathways raise the ceiling
GIP (tirzepatide) and glucagon (retatrutide) recruit additional metabolic mechanisms — greater energy expenditure and fat mobilization — which is why average weight loss climbs from mono- to dual- to triple-agonist in the trial data.
Evidence Snapshot
What the trials show
| Compound | Mechanism | Status & trial weight loss |
|---|
| Semaglutide | GLP-1 mono-agonist | FDA-approved (brand names) for weight management & T2D. ~15% average in pivotal trials. |
| Tirzepatide | GLP-1 + GIP dual | FDA-approved (brand names). ~20–22% in pivotal trials; outperformed semaglutide head-to-head. |
| Retatrutide | GLP-1 + GIP + glucagon triple | Investigational — trials only. ~22–24% at highest doses in Phase 2/3; FDA filing signaled but not approved. |
| AOD-9604 | Lipolytic hGH fragment | Research compound; not FDA-approved as a weight drug. Modest, mechanism-limited effect. |
| MOTS-c | Mitochondrial AMPK signaling | Research compound; metabolic partner, not a standalone weight agent. |
Honest framingOnly semaglutide and tirzepatide are FDA-approved for weight management, under specific brand names. Retatrutide is genuinely promising but investigational. AOD-9604 and MOTS-c are research compounds with supporting, not headline, roles. This hub is education, not a purchasing guide.
Safety Screen
What gets flagged before a GLP-1 is ever considered
A real protocol runs a safety screen first. These are the inputs that change or stop the plan:
- Personal/family history of medullary thyroid carcinoma or MEN2. Contraindication for GLP-1 receptor agonists — full stop.
- Pancreatitis history. Strong caution; requires physician evaluation before any GLP-1.
- Gallbladder disease. Rapid weight loss raises gallstone risk; flagged and monitored.
- Eating disorder or binge-eating history. Appetite-suppressing compounds require careful screening and support.
- Pregnancy, breastfeeding, or trying to conceive. GLP-1 compounds suppressed.
- Severe reflux or gastroparesis. Slowed gastric emptying can worsen these — flagged.
- Diabetes medications already on board. Coordination required to avoid hypoglycemia.
The pointThis screen is the difference between a clinician-built protocol and a vial bought off a forum. The compound is the easy part. Knowing when not to use it is the expertise.
Common Questions
Weight-loss peptide questions answered
Semaglutide vs tirzepatide vs retatrutide — what's the real difference?
Pathway count. Semaglutide activates one gut-hormone receptor (GLP-1). Tirzepatide activates two (GLP-1 + GIP). Retatrutide activates three (GLP-1 + GIP + glucagon). More pathways generally means more weight loss in trials — but retatrutide is still investigational, while semaglutide and tirzepatide have FDA-approved brands. The right one depends on your goal size and diagnosis, not on which is "strongest."
Will I lose muscle on a GLP-1?
You can, if you do nothing to protect it. Fast weight loss from any cause includes lean mass unless you push protein, train with resistance, and often add a GH-axis peptide (CJC-1295 + ipamorelin) to defend muscle. Fat loss and scale weight are different targets — a good protocol optimizes the first, not the second.
What is "food noise"?
The constant background chatter about food — cravings, planning the next meal, intrusive thoughts. GLP-1 compounds act on brain appetite centers and commonly quiet it. Many people describe this as the single most life-changing effect, more than the hunger reduction itself.
Can I use one of these if I've had pancreatitis or gallbladder issues?
Those are exactly the histories that get flagged before a GLP-1 is considered. Pancreatitis and gallbladder disease carry specific cautions, and a personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication. This requires physician evaluation first — no exceptions.
Why once weekly? Can I split the dose?
GLP-1 compounds are dosed once weekly by design — never a 5-on/2-off pattern. Splitting or daily dosing is outside how these are studied and used, and it's one of the locked rules in any properly built protocol.
Not Sure Where You Fit?
Take the 60-second quizAnswer a few questions and get honest, clinician-built education matched to your goal — then a personalized report. No hype, no prescription.
Which peptide is right for you? →
About the Author
SD
Dr. Scott DelBoccio, DMD
Founding Author · PeptideReport.ai
Dr. DelBoccio is a clinician with thirty years of practice and a focus on peptide pharmacology and metabolic medicine. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked — every hub reflects an independent synthesis of the primary literature and the same selection logic that drives the platform's personalized reports. No products are sold on this site.
Full Disclaimer
This hub is for educational and scientific purposes only and does not constitute medical advice, diagnosis, or treatment. Semaglutide and tirzepatide are FDA-approved for weight management only under specific brand names and specific indications; retatrutide is investigational; AOD-9604 and MOTS-c are research compounds not approved for weight loss. Weight-loss pharmacology carries real risks and contraindications and must be evaluated and prescribed by a licensed physician who can assess your history, medications, and labs. PeptideReport.ai does not manufacture, sell, or endorse any peptide preparation. Content addresses adults 21 and older. Evidence and regulatory status continue to evolve.